Embedded Files
In 1992, as the incidence of prostate cancer was rising, debates over the best treatment approach intensified, Congress passed Public Law 102-172. This legislation led to the creation of the Center for Prostate Disease Research (CPDR) with a clear mandate: to investigate prostate cancer and related diseases within the US Military Healthcare System. The responsibility for establishing and overseeing CPDR was entrusted to the Uniformed Services University of the Health Sciences (USU), working in collaboration with the USU-affiliated Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF). CPDR was funded by the Congressionally Directed Medical Research Programs (CDMRP) operated by the US Army Medical Research and Materiel Command (USAMRMC). By 2010, CPDR had earned recognition as a Department of Defense (DoD) Center of Excellence, celebrated for its comprehensive multidisciplinary translational research in the field of prostate cancer.
In 1992, as the incidence of prostate cancer was rising, debates over the best treatment approach intensified, Congress passed Public Law 102-172. This legislation led to the creation of the Center for Prostate Disease Research (CPDR) with a clear mandate: to investigate prostate cancer and related diseases within the US Military Healthcare System. The responsibility for establishing and overseeing CPDR was entrusted to the Uniformed Services University of the Health Sciences (USU), working in collaboration with the USU-affiliated Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF). CPDR was funded by the Congressionally Directed Medical Research Programs (CDMRP) operated by the US Army Medical Research and Materiel Command (USAMRMC). By 2010, CPDR had earned recognition as a Department of Defense (DoD) Center of Excellence, celebrated for its comprehensive multidisciplinary translational research in the field of prostate cancer.
The CPDR integrates a multidisciplinary approach to prostate cancer and continues to make great strides in clinical and basic sciences research for improving the entire spectrum of care to include diagnosis, treatment, management, and follow-up for patients with prostate cancer. CPDR's strategy is to focus investigators on potential breakthrough basic science and clinical research within its three major research programs - Clinical Program, Basic Science Program, and Multicenter National Database - and maintain the core support requirements for all programs.
The CPDR integrates a multidisciplinary approach to prostate cancer and continues to make great strides in clinical and basic sciences research for improving the entire spectrum of care to include diagnosis, treatment, management, and follow-up for patients with prostate cancer. CPDR's strategy is to focus investigators on potential breakthrough basic science and clinical research within its three major research programs - Clinical Program, Basic Science Program, and Multicenter National Database - and maintain the core support requirements for all programs.
To accommodate the needs of its increasingly robust basic science research efforts, in 1999 CPDR expanded from its laboratories within the Department of Surgery at USU to an 18,000- square-foot, stand-alone prostate disease research facility containing laboratory and administrative space in Rockville, Maryland. This facility provided state-of-the-art infrastructure for the Basic Science Research, Multicenter National Database and Administration programs of the CPDR supported by a dedicated team of cancer cell and molecular biologists, epidemiologist, a biostatistician, medical- and bioinformatics specialists and administrative staff.
To accommodate the needs of its increasingly robust basic science research efforts, in 1999 CPDR expanded from its laboratories within the Department of Surgery at USU to an 18,000- square-foot, stand-alone prostate disease research facility containing laboratory and administrative space in Rockville, Maryland. This facility provided state-of-the-art infrastructure for the Basic Science Research, Multicenter National Database and Administration programs of the CPDR supported by a dedicated team of cancer cell and molecular biologists, epidemiologist, a biostatistician, medical- and bioinformatics specialists and administrative staff.
CPDR Basic Science Research Program has been credited with many ground-breaking discoveries leading to a better understanding of the prostate cancer biology and development of promising biomarkers. The CPDR facility in Rockville was also the hub of state-of-the-art prostate cancer research training experience to many short-term and long-term researchers including post-doctoral fellows, urology residents, visiting scientists, medical and graduate students, and summer interns.
CPDR Basic Science Research Program has been credited with many ground-breaking discoveries leading to a better understanding of the prostate cancer biology and development of promising biomarkers. The CPDR facility in Rockville was also the hub of state-of-the-art prostate cancer research training experience to many short-term and long-term researchers including post-doctoral fellows, urology residents, visiting scientists, medical and graduate students, and summer interns.
CPDR Rockville also served as the headquarters of the Multicenter National Database under the USU SoM. During that time, eight DoD medical centers and one civilian site had contributed data from more than 30,000 patients to the CPDR Database. Currently CPDR maintains active operations at WRNMMC, Naval Medical Center-San Diego (NMCSD), Madigan Army Medical Center (MAMC), Tripler Army Medical Center (TAMC), and Brooke Army Medical Center (BAMC). Database sites have been valuable to CPDR for the multi-center clinical and epidemiologic and translational investigations conducted by CPDR investigators and collaborators.
CPDR Rockville also served as the headquarters of the Multicenter National Database under the USU SoM. During that time, eight DoD medical centers and one civilian site had contributed data from more than 30,000 patients to the CPDR Database. Currently CPDR maintains active operations at WRNMMC, Naval Medical Center-San Diego (NMCSD), Madigan Army Medical Center (MAMC), Tripler Army Medical Center (TAMC), and Brooke Army Medical Center (BAMC). Database sites have been valuable to CPDR for the multi-center clinical and epidemiologic and translational investigations conducted by CPDR investigators and collaborators.
In August 2000, CPDR opened a fully dedicated prostate cancer center at the Walter Reed Army Medical Center (WRAMC). The 13,000-square-foot facility accommodated the state-of-the-art clinical research, innovative clinical trials and a comprehensive biospecimen bank supported by dedicated and integrated efforts of urologic-oncologists, physician assistants, clinical research coordinators, medical technologists, and a full-time PhD nurse researcher in education. The prostate cancer center also supports two weekly multidisciplinary clinics with specialists from urology, radiation oncology, and medical oncology as well as comprehensive patient education and support activity.
In August 2000, CPDR opened a fully dedicated prostate cancer center at the Walter Reed Army Medical Center (WRAMC). The 13,000-square-foot facility accommodated the state-of-the-art clinical research, innovative clinical trials and a comprehensive biospecimen bank supported by dedicated and integrated efforts of urologic-oncologists, physician assistants, clinical research coordinators, medical technologists, and a full-time PhD nurse researcher in education. The prostate cancer center also supports two weekly multidisciplinary clinics with specialists from urology, radiation oncology, and medical oncology as well as comprehensive patient education and support activity.
As part of the Base Realignment and Closure (BRAC) process that began in 2005, the WRAMC-CPDR Clinical Research Program moved to a new location. The new state-of-the-art CPDR Clinical Research Program opened at WRNMMC, formerly known as the National Naval Medical Center, in Bethesda, MD, on August 23, 2011. The CPDR-Clinical Research Program is located on the 3rd floor of Building 19 of WRNNMC. The new state-of-the-art, 4,000-square-foot facility at WRNMMC continues to facilitate the clinical and research activities formerly conducted at WRAMC to ensure military beneficiaries suffering from prostate disease are provided exceptional care.
As part of the Base Realignment and Closure (BRAC) process that began in 2005, the WRAMC-CPDR Clinical Research Program moved to a new location. The new state-of-the-art CPDR Clinical Research Program opened at WRNMMC, formerly known as the National Naval Medical Center, in Bethesda, MD, on August 23, 2011. The CPDR-Clinical Research Program is located on the 3rd floor of Building 19 of WRNNMC. The new state-of-the-art, 4,000-square-foot facility at WRNMMC continues to facilitate the clinical and research activities formerly conducted at WRAMC to ensure military beneficiaries suffering from prostate disease are provided exceptional care.
In January 2019, the CPDR moved to a new 20K square foot state of the art translational research facility located at 6720 A Rockledge Dr. Bethesda Maryland, which is co-located with the Murtha Cancer Center Research Program and other Department of Surgery Programs within HJF HQ.
In January 2019, the CPDR moved to a new 20K square foot state of the art translational research facility located at 6720 A Rockledge Dr. Bethesda Maryland, which is co-located with the Murtha Cancer Center Research Program and other Department of Surgery Programs within HJF HQ.
In April 2020, the Chair of the USU-WR Department of Surgery appointment Dr Craig Shriver, MCCRP Director as the acting Chair of the CPDR Research Committee. The committee is made up of clinicians, researchers, pathologists, and epidemiologist from USU, WRNMMC, JPC, HJF, NCI, and other partners. The committee is charged with fostering consensus building, cooperative relationships; communication, strategic planning; program assessment and establishing scientific direction for the CPDR.
In April 2020, the Chair of the USU-WR Department of Surgery appointment Dr Craig Shriver, MCCRP Director as the acting Chair of the CPDR Research Committee. The committee is made up of clinicians, researchers, pathologists, and epidemiologist from USU, WRNMMC, JPC, HJF, NCI, and other partners. The committee is charged with fostering consensus building, cooperative relationships; communication, strategic planning; program assessment and establishing scientific direction for the CPDR.
In June 2020, the USU/CPDR signed into an agreement with the National Cancer Institute, (NCI) Center for Cancer Research (CCR) to formalize the relationship between the parties for future joint scientific research collaborations. The parties work collaboratively on basic science, translational, and human subjects research in a cost neutral manner.
In June 2020, the USU/CPDR signed into an agreement with the National Cancer Institute, (NCI) Center for Cancer Research (CCR) to formalize the relationship between the parties for future joint scientific research collaborations. The parties work collaboratively on basic science, translational, and human subjects research in a cost neutral manner.
CPDR Molecular Lab, Bethesda, MD
CPDR Assay Lab, Bethesda, MD
Dr. Gregory Chesnut performing prostate surgery at WRNMMC.
In July 2020, CDR Gregory T. Chesnut, MD, MC, USN was appointed as the new CPDR Director. He is a urologic oncologist at the WRNMMC, a graduate of the United States Naval Academy in 1999 and USU SOM in 2010 and completed a urologic fellowship at Memorial Sloan Kettering Cancer Center. Dr. Chesnut is also an Associate Professor in the USU-WR Department of Surgery.
In July 2020, CDR Gregory T. Chesnut, MD, MC, USN was appointed as the new CPDR Director. He is a urologic oncologist at the WRNMMC, a graduate of the United States Naval Academy in 1999 and USU SOM in 2010 and completed a urologic fellowship at Memorial Sloan Kettering Cancer Center. Dr. Chesnut is also an Associate Professor in the USU-WR Department of Surgery.
CPDR Continues to provide invaluable prostate cancer research and treatment to Active-Duty members and DoD beneficiaries within the Military Health System. CPDR has been a recognized lead organization in the discovery and translation of biomarkers for the early detection and treatment of prostate cancer for all military service members. With up to 30 years of follow up time, 32,000 prostate sections donated by over 2,000 patients, CPDR leads the AI-generated prognostic models to improve the prediction of disease-free survival.
CPDR Continues to provide invaluable prostate cancer research and treatment to Active-Duty members and DoD beneficiaries within the Military Health System. CPDR has been a recognized lead organization in the discovery and translation of biomarkers for the early detection and treatment of prostate cancer for all military service members. With up to 30 years of follow up time, 32,000 prostate sections donated by over 2,000 patients, CPDR leads the AI-generated prognostic models to improve the prediction of disease-free survival.
Report abuse